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A B S T R A C T   
Background: The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 
patients has been suggested. By using several experimental approaches, we investigated the potential association 
between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing anti-
bodies (NtAb) targeting S, and COVID-19 severity. 
Patients and methods: This unicenter, retrospective, observational study included 51 hospitalized patients (24 at 
the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the 
onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were 
measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood 
counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and 
interleukin-6 (IL-6) were retrieved from clinical charts. 
Results: The overall correlation between levels of both antibody measurements was good (Rho = 0.82; 
P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of 
symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these 
achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0–<0.2) or weak 
(Rho=>0.2–<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro- 
inflammatory biomarkers. 
Conclusions: The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 
levels and COVID-19 severity.   
1. Background 
Coronavirus disease 2019 (COVID-19), caused by severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 
and has been declared a pandemic [1]. Clinical presentation of 
COVID-19 varies widely, ranging from asymptomatic to mild or severe 
forms [2,3]. Worse clinical outcomes are related to an imbalanced im-
mune response skewed toward a Th1 pro-inflammatory profile, which 
leads to the uncontrolled release of cytokines and chemokines, such as 
interleukin-6 (IL-6), that mediates progression into acute respiratory 
distress syndrome, multiorgan failure, and death [4,5]. 
Adaptive humoral immunity is thought to protect from acquiring 
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SARS-CoV-2 infection, of which neutralizing antibodies (NtAb) seem-
ingly play a major role [6]. Although epitopes mapping within all 
SARS-CoV-2 structural proteins have been shown to elicit NtAb, the 
receptor-binding domain (RBD) of the viral spike protein (S) is immu-
nodominant and a highly specific target of most potent NtAbs in 
COVID-19 patients [6–9]. The involvement of functional antibodies in 
SARS-CoV-2 clearance and modulation of COVID-19 severity remains to 
be precisely defined [10]. Data obtained in experimental models indi-
cated that adoptive transfer of neutralizing monoclonal antibodies re-
duces viral burden in the lung, ameliorates local inflammation and 
decreases mortality [7,11,12]. Moreover, passive immunization of crit-
ically ill COVID-19 patients with plasma from individuals who had 
recovered from SARS-CoV-2 infection and seroconverted was associated 
with improved clinical outcomes in uncontrolled case series [13,14]. 
Yet, the possibility that antibodies could potentially trigger immuno-
pathogenic events in SARS-CoV-2-infected patients or enhance infection 
is a major concern [6,15,16]. In this context, higher antibody titers, 
either neutralizing or not, have been reported to be present in patients 
developing severe forms of COVID-19 when compared to mildly symp-
tomatic individuals who did not require hospitalization [17–23]. 
2. Objectives 
Here, we aimed to explore the potential relationship between the 
magnitude of SARS-CoV-2 antibodies binding to RBD and NtAb target-
ing the S protein with the severity of COVID-19 in a cohort of hospi-
talized patients. 
3. Study design 
3.1. COVID-19 patients 
In this unicenter, retrospective observational study, 51 non- 
consecutive hospitalized patients with laboratory-confirmed SARS- 
CoV-2 infection by RT-PCR, admitted to Hospital Clínico Universitario 
of Valencia between March 5 to April 30, 2020, were included. Patients 
were hospitalized within 24 h after seeking medical attention at the 
emergency service. All patients presented with pneumonia and imaging/ 
laboratory findings compatible with COVID-19 [2,3]. Medical history 
and laboratory data were retrospectively reviewed. The current study 
was approved by the Research Ethics Committee of Hospital Clínico 
Universitario INCLIVA (March, 2020). 
3.2. Patient samples 
A total of 93 sera from 51 patients with COVID-19 were included for 
the analyses detailed below. Forty-seven sera were obtained within the 
first two weeks after the onset of symptoms, 32 between the third and 
the forth weeks and 14 afterwards (between days 31 and 45). Sequential 
specimens were available from 20 out of the 51 patients (median 3 
specimens/patients; range 2–6), 17 of whom were in ICU. Sera from 51 
individuals collected prior to the epidemic outbreak (within years 2018 
and 2019) served as controls in the SARS-CoV-2 RBD IgG immunoassay 
and the SARS-CoV-2 neutralizing antibody assays described below. Nine 
patients had tested positive for Coronavirus 229E by the xTAG Respi-
ratory Viral Panel (Luminex Corporation, Austin, Tx, USA). 
Table 1 
Demographic, clinical and laboratory characteristics of patients with COVID-19.  


























17 (2− 67) 9 (2− 22) 36 (8− 67) <0.001 





12 (5− 36) 11 (5− 32) 13 (7− 36) 0.33 
Co-morbidities; 
no. (%) 




1 (0− 5) 1 (0− 3) 2 (0− 5) 0.18  
Comorbidity; median (range) 
Arterial 
hypertension 
23 (45) 11 (41) 12 (50) 0.58 
Chronic renal 
disease 
2 (4) 0 2 (8) 0.22 
Diabetes mellitus 12 (24) 5 (19) 7 (29) 0.51 




4 (8) 2 (7) 2 (8) 0.90 
Myocardial 
infarction 
2 (4) 1 (4) 1 (4) 1.00 
Pulmonar diseasea 7 (14) 2 (7) 5 (21) 0.16 
Tumor 3 (6) 1 (4) 2 (8) 0.48  
Laboratory findingsb; median (range) 
CRP (in mg/l) 44 
(0.8− 273) 
70 (0.8− 242) 24.80 
(1.00− 273) 
0.24 





















IL-6 (pg/mL)c 1012 
(4.6− 5000) 












a Including asthma, atelectasis and chronic obstructive pulmonary disease. 
b The median was calculated in patients with more than one sample. Normal 
values: 12− 300 ng/mL for ferritin, <100 ng/mL for Dimer-D, and <10 mg/L for 
C-reactive protein (CRP), 140–280 U/L Lactic acid dehydrogenase (LDH), 
5–15 pg/ml for IL-6, and 1–4.8 lymphocytes ×109/L. 
c Data available from 18 patients. 
Fig. 1. Correlation between SARS-CoV-2 RBD IgG levels quantitated by ELISA 
and NtAb50 titers measured by a reporter-based pseudotype (VSV-S) neutrali-
zation assay in sera from COVID-19 patients. Rho and P values are shown. 
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3.3. SARS-CoV2-2 RT-PCR 
Nasopharyngeal or oropharyngeal specimens were obtained with 
flocked swabs in universal transport medium (Beckton Dickinson, Sparks, 
MD, USA, or Copan Diagnostics, Murrieta, CA, USA) and conserved at 4 ◦C 
until processed (within 6 h). Undiluted tracheal aspirate samples obtained 
from mechanically ventilated patients were also processed when available. 
Commercially-available RT-PCR kits were used for SARS-CoV-2 RNA 
testing, as previously detailed [24]. 
3.4. SARS-CoV-2 RBD IgG immunoassay 
An enzyme-linked immunosorbent assay (ELISA) was used to quan-
titate IgG antibodies binding to SARS-CoV-2 RBD [25,26]. A detailed 
description of the assay can be found in Supplementary Methods. 
3.5. SARS-CoV-2 neutralizing antibody assay 
A green fluorescent protein (GFP) reporter-based neutralization assay 
Fig. 2. SARS-CoV-2 RBD IgG levels (A) and NtAb50 titers (B) at different time points after the onset of symptoms in patients with COVID-19.  
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which used a non-replicative vesicular stomatitis virus pseudotyped with 
the SARS-CoV-2 spike protein (VSV-S) was optimized as previously 
described (see supplementary methods) [27–29]. We considered high 
NtAb50 titers those ≥1/160, as this is the minimum NtAb titer of plasma 
from COVID-19 convalescent individuals recommended by the FDA for 
therapeutic use [30]. 
3.6. Laboratory measurements 
Clinical laboratory investigation included complete blood count and 
levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydro-
genase (LDH) and interleukin-6 (IL-6) quantitated in sera that were later 
used for SARS-CoV-2 RBD IgGs and NtAb testing. 
Fig. 3. Kinetics patterns of SARS-CoV-2 RBD IgGs (A,B,C) and NtAb (D,E,F) in 20 COVID-19 patients (17 admitted to the intensive care unit).  
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3.7. Statistical methods 
Frequency comparisons for categorical variables were carried out 
using the Fisher exact test. Differences between medians were compared 
using the Mann–Whitney U test Spearman’s rank test was used to assess 
the correlation between continuous variables using the entire dataset. 
Receiver operating characteristic (ROC) curve analysis was performed to 
identify the optimal SARS-CoV-2 RBD IgG level predicting NtAb titers 
above a certain threshold. Two-sided exact P-values are reported. A P- 
value <0.05 was considered statistically significant. The analyses were 
performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). 
4. Results 
4.1. Clinical characteristics of COVID-19 patients 
Patients hospitalized in the pneumology ward (n = 27) and ICU 
(n = 24) were matched for sex and age, the presence of co-morbidities 
and the time elapsed from the day of onset of symptoms to first serum 
sample collection (Table 1). As expected, ICU patients were hospitalized 
for longer periods and the median serum levels of several pro- 
inflammatory biomarkers, (LDH, dimer-D and IL-6) were significantly 
higher in ICU patients, further confirming their association with COVID- 
19 severity [2–5]. Four ICU patients died. 
4.2. Correlation between SARS-CoV-2 RBD IgG levels and neutralizing 
antibody titers 
We first aimed to determine whether SARS-CoV-2 RBD IgGs could be 
used as a proxy for NtAb50 titers. As shown in Fig. 1, the overall corre-
lation between levels of both antibody assays was strong (Rho = 0.82; 
P < 0.001). ROC analysis showed that SARS-CoV-2-RBD IgG levels 
≥1.15 AU/mL predicted the presence of NtAb50 titers ≥160 with a 
sensitivity of 90 % and a specificity of 94 % (Supplementary Fig. 1). 
4.3. Kinetics of SARS-CoV-2 RBD IgGs and neutralizing antibodies 
Overall, serum levels of both antibody tests were seen to increase 
significantly in parallel over time (Fig. 2), although the median peak 
NtAb50 titer was reached earlier (between days 11–20) than that of RBD- 
specific IgGs (between days 20–30). After peaking, NtAb50 levels 
remained stable through the end of the study period, while RBD-specific 
IgGs decreased slightly afterwards. Sequential sera were available from 
20 patients, most of whom (n = 17) were at ICU. The kinetics profile 
from both antibody assays was found to vary widely across patients 
(Fig. 3), some of whom exhibited increasing levels while others dis-
played either constant or fluctuating titers. 
4.4. SARS-CoV-2 RBD IgG avidity 
Avidity of SARS-CoV-2 IgGs in sera from COVID-19 patients was 
assessed by a conventional urea dissociation assay [26]. Overall, AIs 
were very low (median 5 %; range 2–28 %). Most sera (40 out of 51) 
displayed AI ≤ 10 %. Analysis of sequential sera from 20 patients 
revealed that SARS-CoV-2 IgG AI slightly increased over time (Fig. 4). 
SARS-CoV-2 RBD IgG AI did not correlate with NtAb50 titers 
(Rho = 0.07; P = 0.56) 
4.5. SARS-CoV-2 antibodies and COVID-19 severity 
We next compared SARS-CoV-2 RBD IgG and NtAb50 levels in ICU 
and non-ICU patients in sera collected within the first 30 days after the 
onset of symptoms. We did not notice a significant difference in the 
magnitude of either antibody response across groups (Fig. 5). Of note, 4 
ICU patients died, of which two achieved NtAb50 titers ≥1/160 while the 
other two exhibited a 1/80 titer. 
4.6. SARS-CoV-2 antibody levels and biomarkers of COVID-19 prognosis 
Finally, we sought to determine whether the magnitude of SARS- 
CoV-2 RBD IgG and NtAb responses was related to an inflammatory 
state, as inferred from serum levels of CRP, ferritin, Dimer-D, LDH and 
IL-6. For this, we first performed correlation analyses between these 
parameters. Very weak (Rho=>0.0–<0.2) or weak (Rho=>0.2–<0.4) 
correlations (either positive or negative) were found between SARS- 
CoV-2 RBD IgG levels or NtAb50 titers and all selected biomarkers 
when considering the entire data set (Fig. 6) or when analyses were done 
separately for specimens collected at different time frames after the 
onset of symptoms (days 1–15 or days 15–30; not shown). Measure-
ments from both antibody assays weakly correlated with total lympho-
cyte counts. As a complementary approach, we grouped sera into two 
categories (high NtAb50 titers: ≥1/160 and low NtAb50 titers: <1/160), 
and assessed whether median levels of the abovementioned parameters 
differed across groups. We found this not to be the case (Supplementary 
Fig. 2). 
5. Discussion 
Here, in addition to further characterizing the antibody response to 
SARS-CoV-2 in hospitalized COVID-19 patients, we mainly aimed to 
determine whether a relationship could be established between the 
magnitude of SARS-CoV-2 RBD IgG and NtAb levels and the “inflam-
matory state” of patients, which has been shown to directly correlate 
with COVID-19 severity and prognosis [2–5]. 
We found that SARS-CoV-2 RBD IgG levels correlated well with NtAb 
titers, as quantitated by a VSV reporter virus pseudotyped with SARS- 
CoV-2 S protein (VSV-S), thus lending support to the assumption that 
the former parameter is a reasonably reliable proxy for the latter [8,9]. 
Moreover, we could define a SARS-CoV-2 RBD IgG threshold 
(≥1.15 AU/mL) predicting NtAb titers ≥1/160 with high sensitivity and 
specificity, this being the lowest titer of plasma recommended by FDA 
for passive transfer therapy [30]. 
Previous studies have reported a correlation between RBD IgG levels 
and NtAb titers in patients with comparable or less severe clinical pre-
sentations of COVID-19, using either live native SARS-CoV-2 virus, 
engineered SARS-CoV-2 pseudotype virus systems or replication- 
competent SARS-CoV-2 chimeric viruses [18,22,30–36]. Here, the de-
gree of correlation between these two antibody assays was found to be 
strong (Rho = 0.82), but not absolute (Rho = 1), as previously reported 
[18,30–36], which is consistent with data showing that highly immu-
nogenic epitopes within the S protein outside the RBD elicit potent NtAb 
Fig. 4. SARS-CoV-2 RBD IgG avidity indices (AIs) of serial sera from COVID-19 
patients collected at different times following the onset of symptoms. 
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Fig. 5. SARS-CoV-2 RBD IgG levels (A) and NtAb50 titers (B) at different time points after the onset of symptoms in patients with COVID-19 either admitted to the 
intensive care unit or the pneumology ward. P values for comparisons are shown. 
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Fig. 6. Correlation between SARS-CoV-2 RBD IgG levels and NtAb50 titers with serum levels of C-reactive protein (CRP), Dimer-D, ferritin, lactate dehydrogenase 
(LDH), interleukin-6 (IL-6) and absolute lymphocyte counts. Rho and P values are shown. 
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responses [6,37]. 
The kinetics of SARS-CoV-2 RBD IgGs and NtAb followed a predict-
able course [18,22,30–36], with antibody levels in both assays showing 
a consistent increase over time, and reaching a peak within the second 
and third week after the onset of symptoms for NtAb or slightly later for 
RBD-specific IgGs. 
An interesting observation was that SARS-CoV-2 RBD IgGs avidity 
was quite low (<10 %) in most sera, which were collected up to 2 
months following the onset of symptoms, and showed minimal increase 
over time. This antibody avidity maturation pattern is reminiscent of 
that observed during SARS [38]. Remarkably, no correlation was found 
between SARS-CoV-2 RBD IgG AIs and NtAb50 titers. This finding is in 
agreement with the idea that limited to no affinity maturation is 
required from the germline to achieve a potent NtAb response to RBD 
[39]. 
The alleged association between high SARS-CoV-2 antibody levels 
and COVID-19 severity [17–22] is a matter of concern. If found to be the 
case, a plausible explanation for this observation may be that patients 
experiencing severe forms of the disease are exposed to higher and more 
perdurable viral burdens [18]; this, however, would call into question 
the role of antibodies in contributing to SARS-CoV-2 clearance. Alter-
natively, it may simply represent an epiphenomenom in the setting of an 
overall exaggerated immune response driven by “cytokine storms”, or 
may constitute a relevant pathogenetic mechanism involved in lung 
tissue damage (antibody-dependent enhancement) [15]. 
The data presented herein do not support the abovementioned as-
sociation. In effect, we failed to find differences in SARS-CoV-2 RBD IgGs 
or SARS-CoV-2 NtAb50 levels within the first 30 days after the onset of 
symptoms between ICU and non-ICU patients who were matched for 
age, sex and co-morbidities. Furthermore, 2 out of the 4 ICU patients 
who died had relatively low NtAb50 titers (1/80). Liu and colleagues 
[19] showed that oxygen requirement in patients was independently 
associated with NtAb50 levels, as measured by both a pseudotyped re-
porter virus or live SARS-CoV-2 neutralization assay. Nevertheless, this 
finding should be interpreted with caution provided that only 8 ICU 
patients were recruited and these were much older than those in the 
non-ICU group. Wang et al. [18] also reported higher NtAb50 titers 
quantitated by a pseudotyped-virus based neutralization assay in 
severely ill patients as compared to mild COVID-19 patients. Other 
studies including relatively small cohorts also pointed to an association 
of COVID-19 severity with SARS-CoV-2 NtAb [20,22,38]. In our view, 
comparison between studies addressing the abovementioned issue is 
rather problematic because of notable differences in clinical character-
istics and therapeutic management of patients, categorization of 
severity, the timing of serum collection, and methods employed for 
SARS-CoV-2 antibodies detection and quantitation. 
Disregulated synthesis and release of pro-inflammatory cytokines is 
thought to be a pathogenetic hallmark of most severe forms of COVID-19 
[4,5]. Although the mechanisms of COVID-19–induced lung injury 
remain unclear, the so-called “cytokine storm” may likely play a critical 
role in the process of disease worsening and thus in COVID-19 prognosis 
[40]. Here, we investigated whether SARS-CoV-2 RBD IgG and NtAb50 
levels correlate with serum concentrations of ferritin, Dimer-D, CRP, 
LDH and IL-6, which have been consistently shown to be markedly 
increased in patients with progressive disease and poor outcomes [4,5]. 
At most, we observed weak or very weak correlations between the 
antibody assays and these inflammatory biomarkers. Moreover, serum 
levels of the latter overlapped between patients with either high or low 
NtAb50 titers (≥1/160). Taken together, these data argue against a 
robust relationship between the magnitude of the antibody responses 
subjected to analysis herein and the state of inflammation in COVID-19 
patients. To our knowledge, only one pre-print study used a similar 
approach to ours to address this issue [35], reporting a modest corre-
lation (Rho = 0.5) between NtAb50 titers and blood CRP levels. In 
addition, in contrast to what was observed here, a moderate negative 
correlation (Rho=-0.45) between NtAb50 titers and absolute lymphocyte 
counts was observed. As stated above, the comparison between the two 
studies is not straightforward. 
The current study has several limitations. First, its retrospective 
nature. Second, cohort size is relatively small in our study. Third, IL-6 
data was only available from 18 patients (all but one at ICU); in addi-
tion, all these patients were treated with tocilizumab. Fourth, SARS- 
CoV-2 antibodies and inflammatory biomarkers levels were measured 
in the blood compartment, which may not necessarily mirror those in 
lung tissue. Fifth, serum levels of other cytokines (i.e. TNF-α, or IL1-β) or 
chemokines (IFNγ-induced protein 10) that may reflect more accurately 
the overall state of inflammation were not measured [4,5]. Sixth, 
epitope specificities of SARS-CoV-2 antibodies other than for the S 
protein in the case of the neutralization assays or RBD in the case of the 
IgG tests were not assessed. In this sense, antibodies mediating immu-
nopathogenetic events, especially through ADE, are more likely to 
behave as sub- or non-neutralizing and target epitopes outside RBD [4]. 
6. Conclusion 
The data presented herein do not support an association between 
SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity. Further, 
well-powered studies overcoming the abovementioned limitations are 
warranted to solve this question, which is of paramount relevance for 
vaccine design and for the safety of passive transfer therapies with 
plasma from convalescent COVID-19 individuals. 
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